

Financial Tear Sheet

Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

Stock Information

FCSC (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Financial Status Indicator	D
Price	\$0.62
Change (%)	▼ 0.02 (3.13%)
Volume	147,808
52 Week Low	\$0.51
Market Cap	\$17,637,650
Rolling EPS	-1.33
PE Ratio	N/A
Shares Outstanding	28,356,351

Data as of 04/20/18 3:54 p.m. ET



Recent Headlines & Events

04/18/18 - 8:00 a.m.
Fibrocell Announces Review of Strategic Alternatives

Date	Title
04/25/18 2:00 p.m. ET	8th Annual World Orphan Drug Congress USA 2018

04/10/18 - 8:00 a.m.
 Fibrocell to Present at 6th Annual Cell & Gene
 Therapy Investor Day and 2018 World Orphan Drug
 Congress USA

03/19/18 - 8:00 a.m.
 Fibrocell Reports 2017 Financial Results and
 Recent Highlights

	Location Oxon Hill, MD – Washington, DC metro area
05/19/18	International Investigative Dermatology 2018 Location Rosen Shingle Creek Resort Orlando, Florida

SEC Filings

Filing Date	Form
04/18/18	8-K
04/02/18	DEFA14A
04/02/18	DEF 14A
03/19/18	PRE 14A

Corporate Governance

Douglas J. Swirsky	Chairman of the Board
Julian P. Kirk	Director
Marc B. Mazur	Director
John Maslowski	Director
Kelvin D. Moore	Director
Marcus E. Smith	Director
Christine St.Clare	Director

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	41	8.07	43.9	12,456,084
Mutual Fund	11	.25	1.5	436,966
Director and Officer	1	.25	0.4	105,600

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Third Security, LLC	8,267,413	29.2	2,727,273	12/31/17
Sabby Management, LLC	1,128,588	4.0	1,128,588	12/31/17
MSD Partners, L.P.	692,960	2.4	0	12/31/17
Armistice Capital LLC	613,896	2.2	613,896	12/31/17
Anson Funds Management LP.	448,136	1.6	448,136	12/31/17
The Vanguard Group, Inc.	267,280	0.9	-61,296	12/31/17
Point72 Asset Management, L.P.	200,000	0.7	200,000	12/31/17
Renaissance Technologies LLC	128,796	0.5	10,032	12/31/17
Creative Planning, Inc.	111,090	0.4	18,000	03/31/18
Virtu Americas LLC	91,366	0.3	55,164	12/31/17

Data provided by Nasdaq. Minimum 15 minutes delayed.